ArgoMed developed a proprietary, water-induced thermotherapy device and technique to address the non-surgical treatment of benign prostatic hyperplasia (BPH). BPH is a condition that afflicts the majority of men over 60, causing adverse changes in urinary voiding patterns. ArgoMed’s initial product received FDA market approval in 1999, before the company’s assets were acquired by Circon in 2002.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.